Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.
Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.
The conversation is about the delay in the release of GT20029 phase 2 results by Kintor. It also mentions Minoxidil, finasteride, and RU58841 as treatments for hair loss.
A user named "tresslessinseattle" receiving a mysterious package of Eucapil hair loss treatment, which they are considering in combination with Minoxidil and Finasteride treatments to boost the regrowth they have been seeing.
Some people saw improved hair growth when adding tretinoin to their topical minoxidil routine. They combined the two by applying tretinoin before minoxidil.
People have reported hair thickening with Pyrilutamide, particularly using a 1% concentration. Some users are curious about the availability of different concentrations like 0.9%.
Reducing sugar intake may lessen scalp itchiness associated with hair loss, even when using treatments like finasteride. Some users also report similar symptoms while on dutasteride.
The user experienced significant hair regrowth in three months using a capsule containing minoxidil and finasteride. They reported no major side effects and plan to continue the treatment until their late 20s.
Lactobacillus reuteri 6475 is being used by a person who reports healthier hair after one month, despite initial shedding. The discussion includes speculation about its effects on gut bacteria and scalp inflammation.
A user discusses a hair loss treatment combining minoxidil and tretinoin, noting it may enhance absorption. Some users express interest and share positive experiences, while others question its effectiveness without medical evidence.
The user has experienced hair loss stabilization with dutasteride and oral minoxidil but is considering adding RU58841 for potential regrowth. Another user advises that it may take up to 36 months for full results with dutasteride and warns of possible side effects with RU58841.
The conversation discusses the potential of creating a homemade sulforaphane topical for hair loss treatment. Participants mention challenges with sulforaphane stability and reference other treatments like Minoxidil.
A user is experiencing hairline recession and has started using RU58841, applying it to the temples. They are seeking advice on the appropriate dosage for this specific area.
The user observed that stopping nicotine and caffeine improved their scalp health while using oral finasteride. However, relapsing with caffeine and nicotine caused scalp tightness and inflammation.
The post discusses a user's 2-month progress in treating hair loss using topical Du once a week, microneedling, and red light therapy. The user notes that red light therapy is primarily for face and body inflammation but also applies it to the scalp.
The conversation discusses using minoxidil, finasteride, spironolactone, and RU58841 for hair loss treatment. Users share experiences with these treatments, noting side effects and varying effectiveness.
The user experienced severe side effects from finasteride, including cognitive and sexual issues, despite its effectiveness for hair growth. They are considering switching to RU58841 and seek insights from others who have made a similar change.
The user is considering RU58841 and has been using dutasteride since age 17. They are seeking affordable SARD options, mentioning ASC-J9, GT20029, and AH001.
RU58841 is being discussed as a hair loss treatment without using finasteride or dutasteride. Users are sharing their experiences and success with RU58841 alone.
The user is happy with hair regrowth after using finasteride, minoxidil, and microneedling for three months. Others comment on the progress and ask about the routine, lighting, and potential side effects.
The user experiences an itchy scalp and finds relief using shampoo and Zyrtec, which helps with inflammation. They are unsure if the issue is related to histamines or seborrheic dermatitis.
Exosomes are being considered for hair regrowth, with some users reporting initial improvement. One user moved on to using dutasteride and oral minoxidil with positive results.
AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.
RU58841 should be applied directly to the scalp, ideally once a day, a few hours before bed. Some users experienced side effects like shedding and systemic issues when using RU58841 and Minoxidil together, while others reported no side effects when using RU58841 alone.
Minoxidil's effectiveness is limited by the need for sulfation and proper transport to hair follicles, with tretinoin potentially enhancing its effects by promoting enzyme activity and keratinocyte differentiation. Tretinoin may improve minoxidil's response by boosting the expression of necessary enzymes and transporters.
Microneedling for hair regrowth, using a 1.0 dermastamp, is discussed with a focus on achieving slight redness without bleeding. Minoxidil is mentioned as an effective treatment when used after dermastamping.
A 32-year-old is seeing positive hair regrowth after nearly three months using finasteride, oral and liquid minoxidil, and microneedling, and plans to add RU58841. They are considering switching to dutasteride and possibly a hair transplant in the future.
User seeks participants for Verteporfin group buy. Verteporfin, FDA approved, may regenerate hair follicles and sweat glands through heavy microneedling.
Researching whether pyri and enza, which are stereoisomers of each other, share the same features related to CNS penetration/GABA Inhibition; safety and efficacy when used topically at 0.5-1%; and cost comparison between the two treatments.